{
    "clinical_study": {
        "@rank": "60357", 
        "acronym": "PITVIN", 
        "arm_group": [
            {
                "arm_group_label": "Primary Imiquimod", 
                "arm_group_type": "Experimental", 
                "description": "Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months.  A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover.  Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted"
            }, 
            {
                "arm_group_label": "Primary surgery", 
                "arm_group_type": "Active Comparator", 
                "description": "The type of surgery (excision or ablation) will be based on clinical findings and surgeon`s judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, defined as complete clinical response\n      6 months after treatment start, of Imiquimod compared to the standard treatment (surgery)\n      for vulvar intraepithelial neoplasia (VIN)."
        }, 
        "brief_title": "Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Vulvar Intraepithelial Neoplasia", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma in Situ"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed VIN (only usual type, formerly VIN 2-3)\n\n          -  Visible, measurable lesion(s)\n\n          -  Contraception (for premenopausal women)\n\n        Exclusion Criteria:\n\n          -  Evidence of invasion\n\n          -  History of cancer or severe inflammatory dermatosis of the vulva\n\n          -  Pregnancy, lactation\n\n          -  Immunodeficiency\n\n          -  Any treatment for VIN within the previous three months\n\n          -  Known hypersensitivity to imiquimod"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861535", 
            "org_study_id": "KLI293"
        }, 
        "intervention": [
            {
                "arm_group_label": "Primary Imiquimod", 
                "intervention_name": "Imiquimod", 
                "intervention_type": "Drug", 
                "other_name": "Aldara"
            }, 
            {
                "arm_group_label": [
                    "Primary Imiquimod", 
                    "Primary surgery"
                ], 
                "intervention_name": "Surgery", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "Excision", 
                    "Ablation"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imiquimod"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "VIN", 
            "Imiquimod", 
            "Surgery", 
            "HPV", 
            "Patient satisfaction"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "peter.oppelt@gespag.at", 
                    "last_name": "Peter Oppelt, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "state": "Ober\u00f6sterreich", 
                        "zip": "4020"
                    }, 
                    "name": "Dep. of Gynecology and Obstetrics, Landes Frauen- und Kinderklinik Linz"
                }, 
                "investigator": {
                    "last_name": "Angelika Soldan-Salzmann, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Christian.Schauer@bbgraz.at", 
                    "last_name": "Christian Schauer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "state": "Styria", 
                        "zip": "8020"
                    }, 
                    "name": "Dep. of Gynecology, Krankenhaus Barmherzige Br\u00fcder Graz"
                }, 
                "investigator": {
                    "last_name": "Christian Schauer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gerda.trutnovsky@medunigraz.at", 
                    "last_name": "Gerda Trutnovsky, MD", 
                    "phone": "+43 316 385", 
                    "phone_ext": "81081"
                }, 
                "contact_backup": {
                    "email": "olaf.reich@medunigraz.at", 
                    "last_name": "Olaf Reich, MD", 
                    "phone": "+43 316 385", 
                    "phone_ext": "81616"
                }, 
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Department of Obstetrics and Gynecology/ Medical University of Graz"
                }, 
                "investigator": {
                    "last_name": "Gerda Trutnovsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andreas.widschwendter@i-med.ac.at", 
                    "last_name": "Andreas Widschendter, MD", 
                    "phone": "+43 50 504", 
                    "phone_ext": "23055"
                }, 
                "facility": {
                    "address": {
                        "city": "Innsbruck", 
                        "country": "Austria", 
                        "zip": "6020"
                    }, 
                    "name": "Department of Gynecology and Obstetrics, Medical University of Innsbruck"
                }, 
                "investigator": [
                    {
                        "last_name": "Andreas Widschwendter, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Alexandra Ciresa-K\u00f6nig, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "judith.lafleur@bhs.at", 
                    "last_name": "Judith Lafleur, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Linz", 
                        "country": "Austria", 
                        "zip": "4010"
                    }, 
                    "name": "Dep. of Gynecology, Krankenhaus Barmherzige Schwestern Linz"
                }, 
                "investigator": {
                    "last_name": "Judith Lafleur, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "g.bogner@salk.at", 
                    "last_name": "Gerhard Bogner, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "Dep. of Gynecology and Obstetrics, Landeskrankenhaus Salzburg"
                }, 
                "investigator": {
                    "last_name": "Gerhard Bogner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "elmar.joura@meduniwien.ac.at", 
                    "last_name": "Elmar Joura, MD", 
                    "phone": "+43 1 40400", 
                    "phone_ext": "2915"
                }, 
                "contact_backup": {
                    "email": "stephan.polterauer@meduniwien.ac.at", 
                    "last_name": "Stephan Polterauer, MD", 
                    "phone": "+43 316 40400"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "1090"
                    }, 
                    "name": "Department of General Gynecology and Gynecology Oncology, Medical University of Vienna"
                }, 
                "investigator": [
                    {
                        "last_name": "Elmar Joura, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Stephan Polterauer, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia", 
        "other_outcome": [
            {
                "description": "Change from baseline in \"Cervical Dysplasia Distress\" score at 6 months", 
                "measure": "\"Cervical Dysplasia Distress\" Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from Baseline in \"Cervical Dysplasia Distress\" score at 12 months", 
                "measure": "\"Cervical Dysplasia Distress\" questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from Baseline \"Fear of Progression\" score at 6 months.", 
                "measure": "\"Fear of Progression\" Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from Baseline \"Fear of Progression\" score at 12 months.", 
                "measure": "\"Fear of Progression\" questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change from baseline \"Sexual activity\" score at 6 months", 
                "measure": "\"Sexual activity\" Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change from baseline \"Sexual activity\" score at 12 months", 
                "measure": "\"Sexual activity\" questionnaire", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Histochemical analysis of immune cells from vulvar biopsy samples will be performed at baseline and at 6 months. Frozen sections will be prepared and stained with corresponding cell markers. Immune cell populations will be quantified as number of cells per square millimetre and will be compared between the two treatment groups. The following markers and their primary antibodies will be analysed: CD1a, marker for Langerhans cells, CD94, marker for natural killer cells, CD4, marker for T-helper cells, CD8, marker for cytotoxic T-cells and CD207, marker for immature dendritic cells expressing Langerin.", 
                "measure": "Immune cells in the epidermis", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Detailed photos of the overall vulva will be taken. Photos will be compared to photos taken at baseline and judged by 4 independent, blinded observers for aesthetic results.", 
                "measure": "Aesthetic results", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Detailed photos of the overall vulva will be taken. Photos will be compared to photos at baseline and judged by 4 independent, blinded observers for aesthetic results.", 
                "measure": "Aesthetic results", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change of VAS score for pain and pruritus from baseline to 6 months. VAS will be assessed at baseline, 1,2 ,3,4,5 and 6 months.", 
                "measure": "Visual analogue scale (VAS) for assessment of pain and pruritus", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "overall_contact": {
            "email": "gerda.trutnovsky@medunigraz.at", 
            "last_name": "Gerda Trutnovsky, MD", 
            "phone": "+43 316 385", 
            "phone_ext": "81081"
        }, 
        "overall_official": [
            {
                "affiliation": "Medical University of Graz", 
                "last_name": "Gerda Trutnovsky, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Medical University of Graz", 
                "last_name": "Karl Tamussino, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "No clinical evidence of vulvar lesion, i.e. 100% reduction of primary lesion size", 
            "measure": "Complete clinical response", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861535"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Vulvar lesions will be described, measured with calipers, mapped and photographed. The digital photos will be analyzed with a computer program (ImageJ) to calculate the total lesion size in cm\u00b2.  Results will be classified as: no response (NR, reduction in lesion size of 25% or less), weak partial response (wPR, 26-75% reduction), strong partial response (stPR, 76%-99% reduction) and Complete response (CR, 100% reduction).", 
                "measure": "Clinical response/ lesion size", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "At baseline punch biopsies will be taken from the affected areas. The site of the initial biopsy will be photodocumented to ensure that the follow-up biopsy at 6 months is taken from the same site. Histologic results will be classified as response (R): complete disappearance of usual type VIN or reduction to VIN1,or no response (NR). All biopsy samples will be analysed independently by two experienced gynecologic pathologists unaware of the treatment allocation", 
                "measure": "Histologic response", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The number, types and extent of surgical procedures will be recorded. The extent of surgery will be recorded as total operated lesion size (in cm\u00b2, as measured on pre-operative photograph) and relative operated lesion size (percentage of operated lesion size compared with the original pretreatment lesion size)", 
                "measure": "Extent of surgery", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "HPV status will be measured with the qualitative cobas\u00ae HPV Test, Roche, and the the APTIMA \u00ae HPV assay, Gen-Probe.", 
                "measure": "HPV status", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Vulvar lesions will be described, measured with calipers, mapped and photographed. The digital photos will be analyzed with a computer program (ImageJ) to calculate the total lesion size in cm\u00b2.  Results will be classified as: no response (NR, reduction in lesion size of 25% or less), weak partial response (wPR, 26-75% reduction), strong partial response (stPR, 76%-99% reduction) and Complete response (CR, 100% reduction).", 
                "measure": "Clinical response/lesion size", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The number, types and extent of surgical procedures will be recorded. The extent of surgery will be recorded as total operated lesion size (in cm\u00b2, as measured on pre-operative photograph) and relative operated lesion size (percentage of operated lesion size compared with the original pretreatment lesion size)", 
                "measure": "Extent of surgery", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "HPV status will be measured with the qualitative cobas\u00ae HPV Test, Roche, and the the APTIMA \u00ae HPV assay, Gen-Probe.", 
                "measure": "HPV status", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Medical University of Graz", 
        "sponsors": {
            "collaborator": {
                "agency": "Austrian Science Fund (FWF)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}